Latest: FDA Approves New Biosimilar for Oncology Treatment
Medical Research

STAT+: Soleno Therapeutics responds to short seller’s Prader-Willi drug safety claims

by STAT News
0 Comments
0 Mins
Soleno Therapeutics CEO responds to a 415-page short-seller report alleging safety issues tied to the company's newly approved therapy.
Tags:
STAT News
Author

STAT News

Previous Post
Large-Scale Study Suggests Protective Benefit of Hearing Aids in Development of Dementia
Next Post
PA union’s discrimination claims against GP practices could amount to £30m
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago